Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 3/20 | 0.56 |
| ▸ | PLK1 | P53350 | 3/20 | 0.56 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.56 |
| ▸ | SYK | P43405 | 3/20 | 0.56 |
| ▸ | PLK4 | O00444 | 2/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.56 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | PAK4 | O96013 | 2/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6262359 | 0.92 | KDR (0.56) | KDRPTK2PTK2BIGF1RPLK1 | |
| SCHEMBL6259622 | 0.90 | PTK2 (0.67) | KDRPTK2PTK2BIGF1RPLK1 | |
| SCHEMBL6260019 | 0.88 | PTK2 (0.52) | KDRPTK2PTK2BIGF1RPLK1 | |
| Ammonia Solution, Strong SCHEMBL6833389 | 0.85 | PTK2 (0.58) | KDRPTK2PTK2BIGF1RPLK1 | |
| SCHEMBL6260739 | 0.84 | EGFR (0.49) | KDRPTK2PTK2BSYKJAK2 | |
| SCHEMBL6210787 | 0.83 | PTK2 (0.64) | KDRPTK2PTK2BROCK2SYK | |
| SCHEMBL6214284 | 0.83 | PTK2 (0.61) | KDRPTK2PTK2BIGF1RROCK2 | |
| SCHEMBL6210226 | 0.83 | PTK2 (0.61) | KDRPTK2PTK2BIGF1RPAK4 | |
| SCHEMBL6209160 | 0.82 | AURKA (0.59) | PLK1SYKJAK3DYRK1ASTK17A | |
| SCHEMBL6239489 | 0.81 | KDR (0.57) | KDRPTK2PTK2BIGF1RPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | claimed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | KDR 741/4885PTK2 3004/4885PTK2B 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.